Management of Treatment-Resistant Depression: Challenges and Strategies

Cited by (448)

Items 401–448 of 448

1. Additional file 1 of Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
   Carol Jamieson, Vanina Popova, Ella Daly, Kimberly Cooper, Drevets, Wayne C., Heather Rozjabek, Jaskaran B. Singh · 2023 · Figshare
2. Blood Concentrations of Folic Acid and Homocysteine Are Associated with Treatment-Resistant Depression Among Female Depressed Patients
   Iva Radoš, Zrinka Vuksan-Ćusa, Jakov Milić, Marina Šagud, Ana Lončar Vrančić, Nenad Jakšić, Bjanka Vuksan‐Ćusa, Nela Pivac · 2026 · Biomolecules
3. The Impact of Electroconvulsive Therapy on Apoptosis-Related Biomarker Gene Expression in Treatment-Resistant Depression
   Ermin Fetahović, Dragica Selaković, Marina M. Mitrović, Nemanja U. Jovicic, Bojana Simović Marković, Jovan Milosavljević, Branimir Radmanović, Dragan Milovanovic, Biljana Ljujić, Gvozden Luka Rosic et al. · 2026 · Genes
4. Beyond first-line antidepressants: lithium, quetiapine, or esketamine? Integrating meta-analyses and preliminary head-to-head evidence
   David Eckert, Siegfried F. Kasper · 2026 · The World Journal of Biological Psychiatry
5. Mental health promotion through soccer in high-risk communities: a narrative review
   Дилноза Хашимжановна Нарзикулова, Dilfuzakhon Kozokboeva, Saodat Gayupova, Barnokhon TOSHBOYEVA, Kadirov Jonibek, Oybek Ostonov, Hasanova Bo'rigul Hasan qizi, Dilnoza Egamberganova · 2026 · Discover Social Science and Health
6. Case Series of Repetitive Transcranial Magnetic Stimulation in Treatment-Resistant Depression
   Kay Lyn Gue, Chuong Hock Ting · 2024 · Malaysian Journal of Medicine and Health Sciences
7. Gut microbiome signatures associated with depression and obesity
   Carlos Mora‐Martínez, Gara Verónica Molina-Mendoza, María Carmen Cénit, Eva Maria Medina-Rodriguez, Ana Larroya-García, Yolanda Sánchez‐Carro, Leticia González-Blanco, Julio Bobes, Pilar López-García, M. Zandio Zorrilla et al. · 2026 · mSystems
8. Yoga as a modality in occupational therapy practice for adults experiencing mood disorders: A systematic review and meta-analysis
   Tenzin Dolker, Tenzing Dolma, Adrianna Spoerel, Marley Cameron, Briana Bortolin, Anna Colebatch, Candice Crooks, Helena Toolsiedas, Javier Mencia Ledo, Bao-Zhu Stephanie Long et al. · 2026 · British Journal of Occupational Therapy
9. Neuromodulators Generate Multiple Context-Relevant Behaviors in Recurrent Neural Networks
   Ben Tsuda, Stefan C. Pate, Kay M. Tye, Hava T. Siegelmann, Terrence J. Sejnowski A B · 2026 · Neural Computation
10. Color and Major Depressive Disorder ( MDD ): Evidence for the Effects of Value on Color Preferences in Depression
    Fatemeh Akrami, Amirhossein Ghaderi · 2026 · Color Research & Application
11. Predictors of responsiveness to ketamine: An updated systematic review of neuroimaging findings.
    I. Kiani, Giulia Cattarinussi, F. Sambataro, Giandomenico Schiena, G. Delvecchio, L. Squarcina · 2026 · Journal of Affective Disorders
12. WITHDRAWN: Process optimization and antidepression multi-target mechanisms of Total Flavonoids from Hemerocallis citrina Baroni: An integrated approach combining DES-UAE, network pharmacology, and experimental validation
    Guangyu Zhang, Li Gao, Haixia Ji, Taotao Zhang, Yu Zhang · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
13. Advancements in Pharmaceutical Approaches for Psoriasis Management: A Comprehensive Review
    Harmanpreet kaur, Amandeep Kaur Gill, Harjot kaur · 2026 · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine
14. Evaluating the effects of a sedentary time reduction intervention on pain, mood, and quality of life in chronic low back pain: a pilot randomized controlled trial
    Laura D. Ellingson, Madeleine L Connolly, Jeni E. Lansing, Leigh Alison Phillips, Jacob D. Meyer · 2026 · Journal of Behavioral Medicine
15. Neuromodulation with pharmacotherapy: an artificial intelligence perspective
    Sudha Anjali, Jalaja Aswathy, Rebu Sundar, Gayathri Sundar, Rohan M. Goswami · 2026 · Elsevier eBooks
16. Top 50 Cited Articles on the Treatment of Major Depressive Disorder
    Ahmed A Albesher, Nayef A Muflehi, Yazan A Hakami, Jana A Barnawi, Randah E Softah, Luluwah H Al Ghalib, Mayar Bukhari, Reem Abdulaziz M. Almotiri, Maha S Algethami, Shahad W Mahboob et al. · 2026 · Cureus
17. Pre-/pro and synbiotics on anxiety and depression symptoms: a GRADE assessed systematic review and meta-analysis of randomized controlled trials
    Juan Lian, Yu Wang, Gao Feng, Dan Miao · 2026 · Annals of General Psychiatry
18. Cognition in Treatment-Resistant Depression: Obstacles and Challenges?
    Marina Šagud, Nenad Jakšić, Darko Marčinko, Suzana Uzun, Tea Fabijanic, Nela Pivac · 2026 · Advances in experimental medicine and biology
19. Disc1 Gene Expression as a Blood Biomarker for Major Depressive Disorder: A Comparative Study of Fluoxetine and Cognitive-Behavioral Therapy
    Ali Barzegar, Mehdi Pourasghar, Mohammad Bagher Hashemi‐Soteh, Bahareh Baki, Hossein Ghalehnoei · 2026 · Neurochemical Journal
20. Vagus Nerve Stimulation for Neuromodulation: Evolution from Bench to Bedside
    Prasad S. S. V. Vannemreddy, Konstantin V. Slavin · 2026 · Neurology International
21. The Use of Ketamine for Depression in Cancer Patients: A Systematic Review of Efficacy, Safety, and Clinical Applications
    Yogendra Singhal, Pavan Gaurav R, Sreeharsh Saji, Surendra Kumar Pingoliya, Deepinder Kaur Ghera · 2026 · Journal of Pain & Palliative Care Pharmacotherapy
22. References
    2024 · American Psychiatric Association Publishing eBooks
23. Chapter 4. The Myth of Treatment Resistance?
    2024 · American Psychiatric Association Publishing eBooks
24. Evaluating Treatment Sequences in Major Depressive Disorder Using an Open-Source Health Economic Model Based on Stakeholder and Patient Engagement
    Alice Kate Cummings Joyner, Richard H. Chapman, Yuan-Yuan Michelle Cheng, Richard Xie, Larragem Parsley-Raines, Jennifer L. Bright, Warren Stevens · 2026 · Value in Health
25. The interplay between microbiota and the gut-brain axis in treatment-resistant depression
    Amanda Gollo Bertollo, Camila Ferreira Puntel, Giselli Scaini, João Quevedo, Tatiana Barichello, Zuleide Maria Ignácio, Gislaine Z. Réus · 2026 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
26. Assessment of diverse deep brain stimulation targets uncovers a common neural pathway for instantaneous antidepressant effects in rats
    Peixing Qian, Binshi Bo, Minning Li, Gen Li, Yang Liu, Zhifeng Liang, Hongji Sun, Xiaojie Duan · 2026 · Proceedings of the National Academy of Sciences
27. Psychedelics in treatment-resistant depression: a comprehensive review of mechanisms, clinical evidence, and recommendations
    Cielo Amelia Estela-Fernandez, Reem Mohamed Yousif Elsheikh, D F Beatrice, Abdullah A. Alhendal, Chinonso Irene Ewe, Sebastian Y. Montesinos, Jocelyn Wensel, Anushka P Mishra, Asma Ahmed Yousif, Hossam Tharwat Ali · 2026 · Neuropsychiatrie
28. Mental health predictors of treatment engagement and completion in substance use disorder treatment: Within- and between-person evidence from a 15-year Western Australian cohort
    Sascha B. Thal, Hugh Riddell, Carol Daws, James Hunter, Manisha Luhar, BRONWYN J. MYERS · 2026 · Journal of Substance Use and Addiction Treatment
29. Combined Ketamine and Cognitive-Behavioral Therapy: Leveraging Metaplasticity to Enhance Treatment Outcomes
    Morgan S. Hardy, S. William Li, Samuel T. Wilkinson · 2026 · FOCUS The Journal of Lifelong Learning in Psychiatry
30. Medicinal-Edible Plants in Depression Therapy: Mechanistic Basis, Bioactive Compounds, and Translational Perspectives
    Guangyu Zhang, Li Gao, Haixia Ji, Taotao Zhang, Xiaokai Ma, Yinghu Zhao · 2026 · Revista Brasileira de Farmacognosia
31. Reward circuitry predicts the effects of fMRI-guided accelerated prolonged iTBS in treatment-resistant depression.
    Neil Puri, Taylor Ly, Katrina A. Rufino, Elizabeth W. Newlin, Julia Ridgeway-Diaz, Kelly Truong, Hyuntaek Oh · 2026 · Psychiatry Research
32. Dimensional effect profiles in treatment-resistant depression: A naturalistic, prospective head-to-head comparison of arTMS, esketamine nasal spray, and oral brexpiprazole
    Giacomo d’Andrea, Clara Cavallotto, Ottavia Susini, Federica Marsico, Giovanna Mammarella, Gianfranco Tamagnini, Antonio Inserra, Gianluca Mancusi, Giorgio Di Lorenzo, Tommaso Barlattani et al. · 2026 · Journal of Affective Disorders
33. Comparative Efficacy of Esketamine Nasal Spray Versus Quetiapine Extended Release as Adjunctive Treatments for Treatment-Resistant Depression: A Systematic Review
    Neha Ather, Mashal Zahid, Mohammad Hassan, Maryam Zahid, Nouraiz Abbas, Taimoor Rasheed, Hafsa Ahsun, Muhammad Saad Khan, Muhammad Mohsin Khan · 2026 · Annals of Clinical Psychiatry
34. The gut microbiota mediates the antidepressant effects of imipramine: Evidence from fecal microbiota transplantation and prebiotic inulin intervention
    Yonglan Chen, Yuxin Lan, Jingyan Yi, Xiaoyi Qi, Li Liu, Sha Liu, Xinxin Xu, Huan Liu, Yufeng He, Bing He et al. · 2026 · Psychopharmacology
35. INTENSIFY—a randomized, controlled trial to investigate the effect of an early intensified pharmacological treatment for major psychiatric disorders after treatment failure in the current episode: a study protocol
    Cynthia Okhuijsen‐Pfeifer, Alessandro Serretti, Eduard Vieta, Lídia Ilzarbe, Chiara Fabbri, Oliver David Howes, Klaus Oliver Schubert, Scott R. Clark, Dennis Liu, Alex Hofer et al. · 2026 · Trials
36. Patient characteristics, treatment patterns and clinical response in patients with treatment resistant depression starting a new treatment in the clinical setting: a multicenter, observational study in Portugal
    Ricardo Moreira, Patrícia Frade, N. Campeão, Sofia Gomes, A. de M. Lopes, G. Lapa, João Vian, Ana Fonseca, F. Polido, Bernardo C. Barata et al. · 2026 · Frontiers in Psychiatry
37. Comparing trajectories of cognitive functioning in treatment-resistant and non-resistant depression: a multicentre linear mixed-effects analysis
    Viktor T. H. Wahner, Toni Lange, Inga Stonner, Pasquale Paribello, Martina Contu, Marco Pinna, Dobrochna Kopeć, Ewa Ferensztajn‐Rochowiak, Filip Rybakowski, Mara Dierssen et al. · 2026 · Journal of Affective Disorders
38. Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms
    Alana King, Morgan S. Hardy, Taeho Greg Rhee, Samuel T. Wilkinson · 2026 · CNS Drugs
39. Electroconvulsive therapy modulates neurite density and free water in discrete white matter compartments in major depression
    Artemis Zavaliangos‐Petropulu, Paloma Pfeiffer, Madeline Crawford, Vera Norris, Randall T. Espinoza, Pauline Wu, Jennifer L. Kruse, Chris Abbott, Shawn M. McClintock, Yvette I. Sheline et al. · 2026 · Research Square
40. Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic Review
    Xizhen Zhang, Xiaowen Zhang, Haiyu Zhang, Sheng Wei · 2026 · International Journal of Molecular Sciences
41. Protocol of a single‐arm open‐label pilot study of extended rTMS therapy for treatment‐resistant depression (ExTMS study)
    Shun Takahashi, Mitsuhiro Eto, Masahiro Hata, Kazuhiro Shinosaki, Manabu Ikeda · 2026 · Psychiatry and Clinical Neurosciences Reports
42. Excitation-Inhibition Balance and Fronto-Limbic Connectivity Distinguish TMS Treatment Outcomes in Refractory Depression
    Davide Momi, Zheng Wang, Mohammad P. Oveisi, Kevin Kadak, Sorenza P Bastiaens, Jennifer I. Lissemore, Yoshihiro Noda, Jonathan H. Downar, Fidel Vila Rodriguez, Rebecca Strafella et al. · 2026 · Biological Psychiatry
43. Augmentation strategies for intravenous ketamine in treatment-resistant depression: A systematic review and meta-analysis
    Reinhard Janssen‐Aguilar, Jithin Thekkelkuthiyathottil Joseph, Huda F. Al-Shamali, Kaija Taylor, Zixu Zhao, Qiaowei Lin, Wendy Lou, Yanbo Zhang, Andrew Greenshaw, Walter Dunn et al. · 2026 · Journal of Affective Disorders
44. Depressive phenotype shapes behavioral, neuroendocrine and molecular responses to repetitive transcranial magnetic stimulation in preclinical models of depression
    Marta Boffa, Sara Spalletti, Francesca Martella, Cerri Carola, Beatrice Feliciani, Antonio Inserra, Luisa De Risio, Giorgio Di Lorenzo, Giovanni Martinotti, Claudio D’Addario et al. · 2026 · Frontiers in Molecular Neuroscience
45. The severity of treatment-resistant depression and the response to repetitive transcranial magnetic stimulation: a prospective, observational, multi-center clinical cohort study
    Lea Holst, Ana Lisa Carmo, Maria Simonsen Speed, Marie Borg Kusk Petersen, Sónia Pimenta, Pernille Kølbæk, Christiane Gasse · 2026 · Nordic Journal of Psychiatry
46. Right putaminal gray matter change tracks psychomotor recovery after accelerated iTBS in melancholic treatment-resistant depression
    Deng Mao, Guo-Rong Wu, Beatriz Araújo Cavendish, Stefanie De Smet, Sara De Witte, Chris Baeken · 2026 · Journal of Affective Disorders
47. BindingDB Entry 50019997: Hybrid molecules combining GABA-A and serotonin 5-HT
    BindingDB · 2024 · UC San Diego
48. Antipsychotic-related brain changes in first-episode psychosis: a systematic review
    Lucie Métivier, Soumia Benbrika, Hugues Lamothe, Sonia Dollfus, Anaïs Vandevelde · 2026 · Neuroscience & Biobehavioral Reviews